(Q51904661)

17 April 2018

title

[Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994]. (English)

1 reference

17 April 2018

main subject

toxoplasmosis

0 references

cerebral toxoplasmosis

1 reference

7

C Katlama

1 reference

17 April 2018

P Bossi

1

1 reference

17 April 2018

E Caumes

2

1 reference

17 April 2018

P Astagneau

3

1 reference

17 April 2018

T S Li

4

1 reference

17 April 2018

L Paris

5

1 reference

17 April 2018

X Mengual

6

1 reference

17 April 2018

F Bricaire

8

1 reference

17 April 2018

language of work or name

French

0 references

publication date

1 May 1998

1 reference

17 April 2018

Revue de Médecine Interne

published in

1 reference

17 April 2018

volume

19

1 reference

17 April 2018

issue

5

1 reference

17 April 2018

page(s)

313-317

1 reference

17 April 2018

Toxoplasmic encephalitis in AIDS.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Neurologic manifestations of AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Neurologic manifestations of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Toxoplasmosis in the compromised host

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. The BIOTOXO Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Toxoplasma gondii infection in advanced HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Tr

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Intermittent co-trimoxazole prophylaxis against Pneumocystis carinii pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Cerebral toxoplasmosis and co-trimoxazole prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Effect of prophylaxis against Pneumocystis carinii on toxoplasma encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Cotrimoxazole prophylaxis for toxoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Toxoplasma encephalitis in patients with acquired immune deficiency syndrome: diagnosis and response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2898%2980100-8

7 January 2021

10.1016/S0248-8663(98)80100-8

Identifiers

DOI

1 reference

17 April 2018

1 reference

17 April 2018